Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP)
The summary for the Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP): The National Institute on Drug Abuse (NIDA) invites applications to support innovative, integrated preclinical and clinical research to validate novel pharmacotherapeutic approaches and to identify potential compounds that are safe and effective, short-term (to reduce and stop drug use) and long-term (to prolong abstinence) pharmacotherapies for cocaine, methamphetamine and cannabinoid addiction. Significant progress in molecular biology, cell biology, genetics, immunology, neuroscience and behavioral sciences has provided the scientific basis for the development of innovative pharmacological interventions for drug addiction. The Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP) encourages a collaborative enterprise between preclinical and clinical scientists in the conceptualization and proof-of-concept of a pharmacotherapeutic strategy. Novel approaches are of interest for the development of pharmacotherapies for c! ocaine, methamphetamine or cannabinoid addiction treatments which are based on molecular targets for specific receptor subtypes, transporters, intracellular organelles or metabolic pathways to modulate the neurotransmitter systems involved in the drug addiction processes. The applicant must possess the expertise necessary to (i) evaluate the proposed strategy in preclinical systems, and (ii) implement early phase clinical studies in volunteers or target populations to validate the therapeutic modality. The participation of commercial (pharmaceutical, chemical, or biotechnological) organizations is strongly encouraged.
|Federal Grant Title:||Strategic Program for Innovative Research on Drug Addiction Pharmacotherapy (SPIRDAP)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-DA-05-009|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Drug Abuse Research Programs|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Apr 18, 2005|
|Posted Date:||Feb 09, 2005|
|Creation Date:||Feb 09, 2005|
|Archive Date:||May 18, 2005|
|Total Program Funding:||$2,000,000|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:||3|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments County governments City or township governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are not eligible to apply. Native American tribal organizations are eligible. Foreign institutions are not eligible to apply as the primary institution, but may enter into a consortium or subcontract with a domestic institution as the primary applicant.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected]OD.NIH.GOV NIH OER Webmaster
- Similar Government Grants
- • Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
- • Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
- • Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
- • The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
- • The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Ethical Issues in Translational Science Research (R01 Clinical Trial Optional)
- • A Collaborative Network to Optimize Emergency Care of Older Adults with Alzheimers Disease...
- • Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not All...
- • HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Instit...
- • National Dental Practice-Based Research Network Clinical Trial or Observational Study Plan...